 |
|
|
|||||
Another home furnishings retail chain has sought Chapter 11 bankruptcy protection as it deals with higher costs, reduced sales, a downturn in the housing market, and President Trump’s tariffs. American Signature Inc (ASI), parent company of American Signature Furniture and Value City Furniture, said Sunday that it has secured $50 million in debt financing as it seeks a buyer in an auction process. Here’s what to know. What is ASI and why is it bankrupt? Founded it 1948 and based in Columbus, Ohio, American Signature Inc is the parent company of two home furnishings retail chains: American Signature Furniture and Value City Furniture. Combined, the company has 120 stores across 17 states, it said in a court declaration over the weekend. The Value City brand is spread out across more states, with stores in Illinois, Indiana, Kentucky, Maryland, Michigan, Missouri, North Carolina, New York, Ohio, Pennsylvania, and West Virginia. American Signature, meanwhile, has locations in Delaware, Florida, Georgia, and Tennessee. Additionally, the company has distribution centers in Ohio, Georgia, Indiana, and California, two of which are owned and two of which are leased. ASI employs roughly 3,000 people. As for why it’s filing for bankruptcy, the retailer noted that it had experienced a period of rapid growth during the COVID-19 pandemic, but that sales have slipped over the last year. It cites a number of reasons for its dire straits, notably “one of the most severe housing market declines in recent history.” Macroeconomic factors including rising interest rates and inflation have further exasperated the situation for ASI, as have “newly established tariffs.” Which stores are closing as part of this process? The company said in its bankruptcy announcement that it expects stores to remain open throughout the process. However, in court filings it has identified five locations that it plans to close by early next year: Value City Furniture: 2320 Sardis Road North, Charlotte, NC 28227 American Signature Furniture: 1770 Galleria Blvd, Franklin, TN 37067 American Signature Furniture: 2130 Gallatin Pike North, Madison, TN 37115 American Signature Furniture: 2821 Wilma Rudolph Blvd, Clarksville, TN 37040 American Signature Furniture: 2075 Old Fort Parkway, Murfreesboro, TN 37129 Liquidation sales have already begun at these locations and are expected to be completed by the end of January 2026, court filings show. The company has enlisted SB360 Capital Partners to help with store closings and has warned that additional stores may close as the consultation process continues. It was not immediately clear how many job losses are expected. Fast Company reached out to ASI for additional details and will update this post if we hear back. What happens next? ASI has entered into an agreement with a so-called stalking horse bidder owned by the Schottenstein family, whom Columbus Monthly has referred to as the Ohio capital’s “last dynasty.” Holding company Schottenstein Stores Corporation also owns American Signature Inc, meaning the furniture chain could stay in the family. However, American Signature plans to seek a higher bidder during an auction process within about 45 days. American Signature’s bankruptcy follows a similar move by fellow home furnishings retailer At Home, which sought Chapter 11 protection in June and has closed a number of locations this year. This story is developing…
Category:
E-Commerce
World shares and U.S. futures were mixed on Monday after Wall Street was buoyed by revived hopes for an interest rate cut by the Federal Reserve.The future for the S&P 500 was up 0.2% while that for the Dow Jones Industrial Average was nearly unchanged.Germany’s DAX gained 0.5% to 23,201.85, while the CAC 40 edged less than 0.1% lower to 7,978.77. Britain’s FTSE 100 inched up 0.1% to 9,547.77.Markets in Japan were closed for a holiday.Hong Kong’s benchmark, the Hang Seng, rose 2% to 25,716.50. It got a boost from a 4.7% gain for e-commerce giant Alibaba, which has reported strong demand for its updated Qwen AI app. Alibaba is due to report earnings on Tuesday.The Shanghai Composite index rose less than 0.1% to 3,836.77.Australia’s S&P/ASX 200 gained 1.3% to 8,525.10.In South Korea, the Kospi reversed early gains, falling 0.2% to 3,846.06 on heavy selling of automakers.Taiwan’s Taiex added 0.3% and the Sensex in India shed 0.4%.This week, U.S. markets will be closed Thursday for the Thanksgiving holiday, which will be followed by the Black Friday and Cyber Monday retail rushes.After last week’s ups and downs over AI and Nvidia, traders will focus more on “the backbone of U.S. growth, the consumer, whose spending still drives two-thirds of GDP,” Stephen Innes of SPI Asset Management said in a commentary.Data on the U.S. economy was scarce during the 6-week U.S. government shutdown, leaving investors struggling to parse trends in the economy.“This makes any sniff of holiday activity foot traffic, discount depth, card authorizations disproportionately important. In a data desert, even a puddle looks like a lake,” he said.On Friday, the S&P 500 gained 1% and the Dow climbed 1.1%. The Nasdaq composite rose 0.9%. Nearly 90% of stocks in the S&P 500 advanced.It was a fitting finish for a week that left the S&P 500 just 4.2% below its record but also forced investors to stomach the sharpest hour-to-hour swings since a sell-off in April. The jarring moves are testing investors following a monthslong and remarkably smooth surge for stocks, and they come down to two basic as-yet unanswered questions.Have prices for Nvidia, bitcoin and other stars of Wall Street shot too high? And is the Federal Reserve done with its cuts to interest rates, which would boost the economy and prices for investments?Markets took heart from a speech by the president of the Federal Reserve Bank of New York, John Williams, who told a conference in Chile that he sees “room for a further adjustment” to interest rates.Other Fed officials have argued against a December cut, saying inflation is still too high.In the bond market, Treasury yields eased Friday on hopes for cuts from the Fed. Traders are now betting on a nearly 72% probability of a December cut, up sharply from 39% a day before, according to data from CME Group. That helped send the yield on the 10-year Treasury to 4.06% from 4.10% late Thursday.In other dealings early Monday, U.S. benchmark crude oil lost 43 cents to $57.63 a barrel. Brent crude, the international standard, gave up 38 cents to $61.56 a barrel.The U.S. dollar rose to 156.75 Japanese yen from 156.47 yen. The euro climbed to $1.1537 from $1.1516.Bitcoin was up 1.6%, near $86,000. On Friday, it briefly plunged below $81,000 before pulling back toward $85,000. That’s down from nearly $125,000 last month and brought it back to where it was in April, when markets were shaking because of President Donald Trump’s higher tariffs. Elaine Kurtenbach, AP Business Writer
Category:
E-Commerce
Hello and welcome to Modern CEO! Im Stephanie Mehta, CEO and chief content officer of Mansueto Ventures. Each week this newsletter explores inclusive approaches to leadership drawn from conversations with executives and entrepreneurs, and from the pages of Inc. and Fast Company. If you received this newsletter from a friend, you can sign up to get it yourself every Monday morning. Being a life sciences CEO is not for the faint of heart. Drug discovery and patent approvals are costly and time-consuming, and even if an executive can steer a company to clinical trials, theres a very small chance the product will be commercialized. One study says that 90% of clinical drug development fails because the treatment didnt have its intended impact, had the wrong formulations, or harmed patients. You have a business challenge, a science challenge, a clinical trial challenge, and a regulatory challenge, says Kevin Conroy, CEO of the colorectal cancer screening company Exact Sciences. Its like solving a complex puzzle, and theres simply no guarantee of success. When companies do solve that puzzle, the rewards can be huge: As Modern CEO went to press, Exact Sciences announced it was selling to Abbott in a deal valued at $21 billion. Still, biotech and health technology companies are now confronting an additional burden: simmering science skepticism. Pew Research Center found that in 2024, 76% of Americans believed that scientists act in the publics best interest, up slightly from 2023 but down 10 points from pre-pandemic levels. A new survey from Pew shows that 24% of parents of school-age children question whether vaccines have undergone enough safety testing. Rebuilding trust in science Some lawmakers are fanning the flames. Health and Human Services secretary Robert F. Kennedy Jr. has called for changes in the ways vaccines are tested. The White House has cut budgets at the National Institutes of Health and the National Science Foundation, and moved to terminate federal funding to universities, all of which participate in the funding of medical and science research. Conroy says the current environment is a call to action to the biosciences industry to help rebuild trust with the public and lawmakers. How can we in this field show success that brings back a stronger belief in science, in data, in clinical studies, in evidence generation? he asks. I think its our responsibility to do that. According to Conroy, Exact Sciences isnt facing any societal or political headwinds. It makes a colon cancer test (if youre a certain age, youve probably been served ads for its Cologuard Kit) that will screen five million people for cancer this year. Science skepticism hasnt touched cancer screening, he says. People on the left and right are touched equally by cancer. Still, Exact Sciences and other science companies have benefited from an ecosystem of government-funded research, rigorous approvals, and endorsements that make the U.S. a biotech innovation powerhouse. Exact Sciences was founded in 1995 by an engineer who wanted to develop an alternative to colonoscopies, but the company struggled for years to develop a test. Conroy joined in 2009 after meeting with David Ahlquist, a Mayo Clinic physician who had spent 20 years researching noninvasive colon cancer detectionresearch funded by the National Institutes of Health, the National Cancer Institute, and the Mayo Clinic College of Medicine and Science. Exact Sciences collaborated with Ahlquist on an approach that tests a patients stool for abnormal DNA or blood cells that might indicate the presence of colon cancer. Cologuard received FDA approval in 2014, after a huge clinical trial involving 10,000 patients; that same year the Centers for Medicare and Medicaid Services said it intended to cover the test, and the American Cancer Society included the test in its colon cancer screening guidelinesa key recommendation that helped build public trust in the at-home kit. Exact Sciences would not be here without federally funded research at the Mayo Clinic, Conroy says. Follow the data Conroy notes that all businesses can gain from a scientific approachrunning experiments, conceding when something doesnt work (even if youve invested time and money in the research), and following the data. At Exact Sciences, such rigor extends beyond the lab. Before the company launched its kits, the team tested two different product designs for sample collectiona scoop and a container. The team thought consumers would favor the scoop, but research showed 85% of users preferred the container. We would have made a big mistake if we had trusted our gut, Conroy says. A lot of times youre so passionate as a CEO, you skip all of those steps and just bulldoze your way toward the answer youd like to see. Im as guilty of that as the next CEO. I asked Conroy how biotech executives can help restore trust in science and rally support for the broader system of grants and research funding now under fire. He notes that he travels to Washington from Exact Sciences headquarters in Madison, Wisconsin, every quarter to meet with lawmakers, largely to advocate for early detection of diseases but also to talk about innovation and discovery. Every CEO in this field should be doing the same thing. Its too important for Americas competitiveness, he says. Deadline extended Were extending the deadline for Modern CEO of the Year nominations by a few days. If you or someone you know has had a standout 2025, please fill out this nomination form by November 28. Well name the Modern CEO of the Year on December 29. Read more: science in focus This Sam Altmanbacked CEO is using AI to get drugs to market faster The most innovative biotech companies of 2025 Why Jennifer Doudna is one of the 10 most innovative people of the last 10 years
Category:
E-Commerce
All news |
||||||||||||||||||
|
||||||||||||||||||